2nd ESMO Consensus Conference on Lung Cancer : non-small-cell lung cancer first-line/second and further lines in advanced disease

Besse, B., Adjei, A., Baas, P., Meldgaard, P., Nicolson, M., Paz-Ares, L., Reck, M., Smit, E.F., Syrigos, K., Stahel, R., Felip, E., Peters, S., Stahel, R., Felip, E., Peters, S., Kerr, K., Besse, B., Vansteenkiste, J., Eberhardt, W., Edelman, M., Mok, T., O'Byrne, K., Novello, S., Bubendorf, L., Marchetti, A., Baas, P., Reck, M., Syrigos, K., Paz-Ares, L., Smit, F.E., Meldgaard, P., Adjei, A., Nicolson, M., Crinò, L., Van Schil, P., Senan, S., Faivre-Finn, C., Rocco, G., Veronesi, G., Douillard, J.Y., Lim, E., Dooms, C., Weder, W., De Ruysscher, D., Le Pechoux, C., De Leyn, P., & Westeel, V. (2014) 2nd ESMO Consensus Conference on Lung Cancer : non-small-cell lung cancer first-line/second and further lines in advanced disease. Annals of Oncology, 25(8), pp. 1475-1484.

View at publisher


To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, early stage disease and locally-advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on 1st line / 2nd and further lines of treatment in advanced disease. © The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

Impact and interest:

46 citations in Scopus
Search Google Scholar™
43 citations in Web of Science®

Citation counts are sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

ID Code: 78356
Item Type: Journal Article
Refereed: Yes
Additional Information: Cited By (since 1996):2 Export Date: 2 November 2014 CODEN: ANONE Correspondence Address: Besse, B.; ESMO Guidelines Working Group, ESMO Head Office, Via, L. Taddei 4, CH-6962 Viganello-Lugano, Switzerland; email: clinicalguidelines@esmo.org Chemicals/CAS: afatinib, 439081-18-2, 850140-72-6, 850140-73-7; bevacizumab, 216974-75-3; carboplatin, 41575-94-4; cisplatin, 15663-27-1, 26035-31-4, 96081-74-2; crizotinib, 877399-52-5; dabrafenib, 1195765-45-7, 1195768-06-9; denosumab, 615258-40-7; docetaxel, 114977-28-5; epidermal growth factor receptor, 79079-06-4; erlotinib, 183319-69-9, 183321-74-6; gefitinib, 184475-35-2, 184475-55-6, 184475-56-7; gemcitabine, 103882-84-4; mitomycin, 1404-00-8, 50-07-7, 74349-48-7; navelbine, 71486-22-1; paclitaxel, 33069-62-4; pemetrexed, 137281-23-3, 150399-23-8; sorafenib, 284461-73-0; trastuzumab, 180288-69-1; vandetanib, 338992-00-0, 338992-48-6, 443913-73-3; vinblastine, 865-21-4; zoledronic acid, 118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7
Keywords: Consensus, Esmo, Further lines, Non-small-cell lung cancer, afatinib, bevacizumab, carboplatin, cisplatin, cisplatin derivative, crizotinib, dabrafenib, denosumab, docetaxel, epidermal growth factor receptor, erlotinib, gefitinib, gemcitabine, mitomycin, navelbine, paclitaxel, pemetrexed, placebo, sorafenib, taxane derivative, trastuzumab, vandetanib, vinblastine, zoledronic acid, adenocarcinoma, advanced cancer, article, blood toxicity, bone metastasis, brain metastasis, cancer chemotherapy, cancer growth, cancer incidence, cancer staging, cancer survival, consensus development, drug efficacy, drug rechallenge, drug substitution, drug tolerability, drug withdrawal, febrile neutropenia, gain of function mutation, gene mutation, gene rearrangement, human, lung non small cell cancer, maintenance therapy, meta analysis (topic), monotherapy, multiple cycle treatment, mutation, neutropenia, phase 3 clinical trial (topic), primary medical care, priority journal, progression free survival, quality of life, randomized controlled trial (topic), secondary health care, treatment response, unspecified side effect
DOI: 10.1093/annonc/mdu123
ISSN: 0923-7534
Subjects: Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > ONCOLOGY AND CARCINOGENESIS (111200)
Divisions: Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
Copyright Owner: Copyright 2014 Oxford University Press
Deposited On: 03 Nov 2014 23:40
Last Modified: 04 Nov 2014 23:37

Export: EndNote | Dublin Core | BibTeX

Repository Staff Only: item control page